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Molecular signaturesalyses provided insight into understanding transcript changes during cancer
progression; however, a reproducible signature underlying breast carcinogenesis has yet to be little available.
We utilized gene expression proﬁling to deﬁne molecular signatures associated with transformation and
cancer progression in a series of isogenic human breast cancer cell lines including a normal, benign,
noninvasive and invasive carcinoma. Clustering analysis revealed four distinct expression patterns based on
upregulation or downregulation patterns. These proﬁles proved quite useful for describing breast cancer
tumorigenesis and invasiveness. Downregulation of TNFSF7, S100A4, S100A7, S100A8, and S100A9 (calcium-
binding protein family), and upregulation of kallikrein-5 and thrombospondin-1 were associated with
transformation and progression of breast cancer cells. Importantly, downregulation of the genes was
reversed by treatment with silencing inhibitors, implying the potential roles of epigenetic inactivation in
breast carcinogenesis. Exogenous expressions of S100A8 and S100A9 inhibit growth in benign and
noninvasive carcinoma cells, suggesting their negative role in cell proliferation. The data presented here may
facilitate the identiﬁcation and functional analyses of prognostic biomarkers for breast cancer.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe transformation of normal epithelium through carcinoma in
situ to invasive malignancy is correlated with the altered gene
expression, which results in alterations in biological pathways, as
well as with genetic changes such as mutation of speciﬁc genes and
chromosomal aberrations [1–3]. At least three classes of genes play
key roles in the process: proto-oncogenes, tumor-suppressor genes,
and genes involved in DNA repair mechanisms [4]. Mutations in these
genes lead to instability of normal growth and differentiation.
Ultimately, this instability results in clonal selection of variants with
defective regulatory growth mechanisms, and invasion and destruc-
tion of normal tissues [5]. Breast tumor progression is generally
recognized by histological changes, which are not sufﬁcient to predict
the behavior of tumor progression accurately [6]. In combinationwith
histology, characterization of genetic change permits more precise
classiﬁcation and diagnosis of tumor progression [7].
Comprehensive gene expression proﬁling analysis is best per-
formed using microarrays, which allow clustering of genes based on
expression patterns [8–12]. Microarray analyses on cancer cell lines
indicated that genes with the same origin or from the same organsei University, 134 Shinchon-
+82 2 312 5657.
l rights reserved.cluster together [13]; however, a comprehensive and more reliable
picture of gene expression changes from healthy cells to invasive
breast cancer has not been determined, due, in part, to difﬁculties in
obtaining specimens with the same genetic background or to
heterogeneity in tissue samples [10]. The MCF10 cell lines provide
an opportunity to study breast cancer initiation, development, and
progression systemically. The MCF10 cell line was initiated as a mortal
cell line (MCF-10M), from which the two immortal derivatives MCF-
10A, or attached cells, and MCF-10F, or ﬂoating cells, were originated
[14]. Since the MCF-10A line was not tumorigenic, the cells were
transformed to benign proliferation (MCF-10AT1 [15] and MCF-
10AT1kcl2 [16]), carcinoma in situ (MCF-10DCIS.com [17]), and
invasive carcinoma (MCF-10CA1h cl2 [18], MCF-10CA1d cl1 [19], and
MCF-10CA1a cl1 [19]). When losses and gains of loci in these lines
were determined using the multiplex ligation-dependent probe
ampliﬁcation assay (MLPA), CDKN2A and CDKN2B were lost, and
MYC was gained in benign cells [20]. Progression to the in situ
carcinoma stage accompanied gains of IL13, VEGFA, HRAS, TRAF2, and
BCAS2. In addition, further progression to invasiveness involved
gains of IL12A and MME. The experiment, however, only examined a
limited number (112) of human genome sites.
Here, we report a comprehensive microarray analysis of gene
expression in a series of human breast cancer cell lines including
normal, benign, carcinoma in situ, and invasive carcinoma. Identiﬁed
genes were grouped into four groups according to their expression
pattern. Genes of Group I and III exert positive effects on tumorigenesis
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progression. Expression of the selected transcripts was conﬁrmed by
RT-PCR and immunoblot analyses. From these identiﬁed genes, at least
ﬁve genes, including TNFSF7, S100A4, S100A7, S100A8, and S100A9,
were downregulated during transformation and progression of breast
cancer cells via epigenetic silencing by DNA methylation and/or
histone deacetylation. Exogenous expression of S100A8 and S100A9
inhibit growth in benign and noninvasive breast cells, supporting that
the loss of their expression in breast tumor cells is related to cell
proliferation. Thus, four distinct expression patterns that were shaped
by epigenetic changes describe differences in molecular events
associated with transformation and progression to breast cancer in
the isogenic MCF10 model.
Results
Four distinct groups of gene expression patterns demonstrate
transformation and tumor progression in a series of isogenic human
breast cancer cell lines
To identify a comprehensive set of transcripts that are deregulated
during the development of breast cancer, we performed microarray
analysis using Illumina Beadchip arrays on a series of isogenic breast
cell lines (MCF10 model). These cells included the untransformed
outgrowths (MCF-10A), benign proliferation (MCF-10AT1 and MCF-
10AT1kcl2), carcinoma in situ (MCF-10DCIS.com), and invasive breast
carcinoma (MCF-10CA1h cl2, MCF-10CA1d cl1, and MCF-10CA1a cl1)
lines. Comparisons of transcripts that were either upregulated or
downregulated more than two-fold (Figs. 1A and B) revealed thatFig. 1. Microarray analysis of a series of MCF10-derived breast cancer cell lines. Microarray
background including the untransformed outgrowths (MCF-10A [CTL]) and six transformed
MCF-10AT1kcl2 [1k]), carcinoma in situ (MCF-10DCIS.com [com]), and invasive carcinoma (
cluster analysis were carried out with the Euclidean Program to group and display genes with
were compared with the transcript level of the untransformed MCF-10A. (A) The clusters of
(Group B) genes. Green color indicates downregulated genes while red color does upregula5150 genes distinguish the six transformed cell lines from the
untransformed MCF-10A cells. Among them, a subset of 1679 genes
was found to remain constantly upregulated from benign prolifera-
tion to the invasive stages (Group A in Fig. 1B) while a set of 1558
genes was downregulated in the more advanced stages (Group B in
Fig. 1B).
In order to investigate the possible role of genes in tumor
progression more in detail, the genes were classiﬁed into four groups
based on their expression pattern (Figs. 2A and B, Supplemental
Tables 1S and 2S). Group I genes are upregulated in benign
proliferating cells while Group II genes were downregulated in
these cells. Group I and Group II genes are therefore involved in the
transition to benign proliferation. Genes that were upregulated
beginning in carcinoma in situ cells were assigned to Group III while
genes that were downregulated beginning in carcinoma in situ cells
were assigned to Group IV. Regulation of Group III and Group IV genes
is required for the transition from benign proliferation to noninvasive
carcinoma. Thus, genes of Group I and III have positive roles on tumor
progression whereas genes of Group II and IV play negative roles in
tumor progression.
The majority of genes clustered in Group I were involved in
signal transduction, development, cell structure and motility,
nucleic acid metabolism, protein metabolism, lipid metabolism,
or cell proliferation and differentiation, although some of these
genes were related to other functional classes (Fig. 3). Compared to
other function classes, the genes involved in signal transduction,
development, and cell structure and motility comprised a higher
proportion. These Group I genes included ANXA1, PRICKLE1, FLNB,
DYNC1I1, AXL, FAM107B, ERRFI1, PRICKLE1, MFNG, FLII, SHR00M3,analysis was performed on a series of breast cancer cell lines with the same genetic
cell lines recapitulating various stages of benign proliferation (MCF-10AT1 [AT1], and
MCF-10CA1h cl2 [1h], MCF-10CA1d cl1 [1d] and MCF-10CA1a cl1 [1a]). Tree-view and
a greater than two-fold change in expression. The changes in expression of each cell line
all microarray data. (B) Separated clusters of upregulated (Group A) or downregulated
ted genes. In addition, intensity of color is correlated with gene expression levels.
Fig. 2. Classiﬁcation of four different expression patterns reveals tumor progression stages in MCF10-derived breast cancer cell lines. The genes were classiﬁed by the stage of tumor
progression critical for changes in gene expression as well as whether the changes were upregulated or downregulated. (A) The schematic model for grouping. Genes upregulated
following benign proliferation were assigned to Group I while genes downregulated following benign proliferation were assigned to Group II. Genes upregulated beginning in
noninvasive carcinomawere designated Group III while genes downregulated beginning at noninvasive carcinomawere designated Group IV. (B) Microarray data grouped based on
the above designations. The following abbreviations were used: CTL, MCF-10A (untransformed) as control; AT1, MCF-10AT1 (benign proliferation), 1k, MCF-10AT1kcl2 AT1 (benign
proliferation); com, MCF-10DCIS.com (carcinoma in situ); 1a, MCF-10CA1acl1 (invasive); 1d, MCF-10CA1d cl1 (invasive); and 1h, MCF-10CA1h cl2 (invasive carcinoma).
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In addition, Group II exhibited a similar pattern, but the most altered
genes were speciﬁcally related to immunity and defense (Fig. 3).
RAET1G, SEPP1, PTGS1, FABP6, FABP5, CRAT, S100A7, S100A8,
S100A9, MARK1, LRG1, FABP6, SOX15, and ID1 were Group II genes
that were downregulated.
The genes of Group III were also classiﬁed to functional classes
such as signal transduction, immunity and defense, development,
and cell structure and motility (Figs. 2 and 3). Interestingly, Group III
genes were involved in cellular metabolisms including carbohydrate,
amino acid, and phosphate as well as protein and nucleic acids,
suggesting that alterations in cellular metabolism are a prerequisite
for the transition to noninvasive carcinoma. Group III includes genes
such as SHMT2, SPTBN1, ARTN, BMP7, GDF15, ADAM19, APOBEC3G,
HDAC9, FOXA1, MST1R, EREG, TGFA, RGS17, PRSS21, ST3GAL5, CHSY3,
and TGM2.Group IV contained a smaller subset of genes relative to the other
groups. The functional classes of theGroup IV genes are similar to those
of Group III: signal transduction, development, nucleic acid metabo-
lism, immunity and defense, and lipid metabolism (Figs. 2 and 3).
Unlike Group III, Group IV contained only very small number of genes
involved in cell motility, cell proliferation, transport, protein trafﬁc,
oncogenesis, and amino acid metabolism (Fig. 3). These data are
consistent with the opposing expression patterns and their proposed
opposing roles in tumor progression (Fig. 2A). In other words, genes of
Group III may have positive effects on tumor progression while genes
of Group IV may play negative roles in tumor progression. Further-
more, Group IV includes apoptosis-related genes including DUSP1,
PYCARD, CRADD, PTPRZ1, TNF, PYCARD, TNFSF10, PCBD2, KLF10,
BCL11B, LRRC8E, and VAV3. Downregulation of these Group IV genes
may be critical for tumor progression to invasive stages via suppression
of apoptosis mechanism.
Fig. 3. Functional classes of transcripts for each group. The genes of each group from Fig. 2 were classiﬁed based on the gene ontology annotation. The length of the bar is proportional
to the number of genes altered (x-axis).
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progression of breast cancer cells
Microarrays offer a fast and comprehensive look at gene expres-
sion; however, the data from these experiments do not always reﬂect
the actual expression of target genes at both transcript and protein
levels. Thus, we ﬁrst performed semiquantitative RT-PCR analysis to
determine whether the microarray data represent the steady-state
levels of transcript levels (Fig. 4) following real-time quantitative PCR
andWestern blotting. Target genes were selected from the four groups
(Fig. 2) on the basis of fold-changes and potential signiﬁcance in
progression of breast cancer cells. In addition, several genes induced
(Fig. 4C) or suppressed (Fig. 4F) only in the benign stage were also
selected for the analysis. The expression patterns were largely
consistent between the microarray and the RT-PCR data (Fig. 4). All
Group I genes testedwere upregulated in the six transformed cell lines
compared to the control MCF-10A cells. Namely, most Group I genes
including THBS1, MIA, MGP, AXL, and CEACAM1, were shown to be
induced from the benign stage to invasive carcinoma (Fig. 4A). The
TNFRSF12A, RAPGEF3, NFE2L3, and GPRC5A genes that were originally
classiﬁed as Group I genes were upregulated only from carcinoma in
situ cells to invasive carcinoma cells (Fig. 4B). Thus, these results
supported their reclassiﬁcation to Group III.
Similarly, the Group II and IV genes also exhibited expression
patterns consistent with the microarray data. The Group II genes that
were examined exhibited two distinct expression patterns: (1)
moderate reduction of the mRNA level just after the benign stageand maintenance of this level during tumor progression (TNFSF7
(CD70)) and (2) dramatic reduction of the mRNA level from benign
proliferation to the invasive stage (SCGB1A1 (uteroglobin), S100A8, and
S100A9) (Fig. 4D). These results conﬁrm that transformation of normal
breast cells requires inactivation or suppression of Group II genes.
Moreover, transcript levels of the Group IV genes S100A4, GLI3, and
FOLR1 were reduced just after the transition from the benign stage
to the noninvasive stage (Fig. 4E). These data also conﬁrm that
inactivation or suppression of these genes is required for further
progression of benign tumor cells. In addition, the genes induced
(VCAN and TNC), and suppressed (cystatin A (CSTA)) only in the benign
stage displayed RT-PCR results consistent with the microarray data
(Figs. 4C and F). Furthermore, expression patterns of genes from the
four different groups (shown in Fig. 4) were re-conﬁrmed by real-time
quantitative PCR (Supplemental Table 3S).
To assess whether the steady-state levels of the transcripts
represent actual protein levels, we performed immunoblot analysis
on the translated products of selected transcripts which the antibodies
are commercially available (S100A4, S100A8, S100A9, KLK5, THBS1,
MIA, MECP2, and TMEM16A). As shown in Fig. 5, the protein
expression patterns were also largely consistent with the results of
the gene microarrays, semiquantitative RT-PCR, and real-time quanti-
tative PCR. A few genes such as MIA, MECP2, and TMEM16A, however,
did not exhibit any consistency between the transcript and protein
levels (data not shown). Together, at least the ﬁve selected transcripts
such as S100A4, S100A8, S100A9, KLK5, and THBS1 would be good
candidates for additional studies to determine their roles in breast
Fig. 4. Semiquantitative evaluation of selected transcripts by RT-PCR analyses. Gene expression was analyzed by semiquantitative RT-PCR analyses to determine whether the
microarray data represents the existing transcript levels. GAPDH was utilized as an internal control. The sequences of primer sets and reaction conditions are listed in Supplemental
Table 4S. A subset of genes was selected from the microarray data for analysis: (A) Group I genes that gradually increased with tumor progression, (B) Group III genes upregulated in
noninvasive and invasive carcinomas, (C) genes only induced in the benign proliferation stage, (D) Group II genes that exhibit a gradual decreasewith tumor progression, (E) Group IV
genes that are downregulated in noninvasive and invasive carcinomas, and (F) genes only suppressed in the benign proliferation stage. Several genes including NFE2L3, TNFRSF12A,
and GPRC5A, which were originally designated as Group I based on the microarray data, were reclassiﬁed to Group III after RT-PCR and are shown in panel (B). Cell lines used are as
follows: CTL, MCF-10A (untransformed) as control; AT1, MCF-10AT1 (benign proliferation), 1k, MCF-10AT1kcl2 AT1 (benign proliferation); com, MCF-10DCIS.com (carcinoma in situ);
1a, MCF-10CA1acl1 (invasive); 1d, MCF-10CA1d cl1 (invasive); and 1h, MCF-10CA1h cl2 (invasive carcinoma).
Fig. 5. Western blot analysis of selected transcripts. Immunoblot analysis of selected
genes conﬁrmed the expression patterns of mRNA abundance determined by RT-PCR.
Antibodies speciﬁc to THBS1, KLK5, S100A4, S100A8, S100A9, GAPDH, and tubulin were
hybridized to the blots containing proteins from the following cell lines: CTL, MCF-10A
(untransformed) as control; AT1, MCF-10AT1 (benign proliferation), 1k, MCF-10AT1kcl2
AT1 (benign proliferation); com, MCF-10DCIS.com (carcinoma in situ); 1a, MCF-
10CA1acl1 (invasive); 1d, MCF-10CA1d cl1 (invasive); and 1h, MCF-10CA1h cl2 (invasive
carcinoma). GAPDH and tubulin were used as loading controls.
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markers for breast cancer.
Candidate genes that can be regulated by epigenetic silencing
Epigenetic inactivation of tumor suppressors is a recognized event
in tumor progression. In particular, hypermethylation of CpG islands
near the promoter region of tumor-suppressor genes plays an
important role in the development of cancer [21,22]. Thus, we
examined epigenetic changes important in progression of breast
cancer cells. To identify target genes regulated by epigenetic silencing,
we examined whether downregulation of the selected Group II and IV
transcripts was recovered by treatment with silencing inhibitors such
as the DNA methyltransferase inhibitor 5′-aza-2′-deoxycytidine (5′-
aza-dC) and the histone deacetylase inhibitor sodium butyrate.
Treatment with 5-aza-dC and sodium butyrate, indeed, reversed the
transcript levels of TNFSF7 (CD70), S100A4, S100A7, S100A8, and
S100A9 in the transformed cell lines to that of the untransformed
MCF-10A cells (Fig. 6). These results suggest that at least these ﬁve
genes involved in calcium signaling or the immune response can be
regulated by an epigenetic silencing mechanism such as DNA
methylation and/or histone deacetylation. The presented data may
support the hypothesis that the loss of the expression of the selected
genes via epigenetic silencing is related to growth in breast cancer
cells. Further studies will address the regulation of these selected
genes by epigenetic silencing.
Fig. 6. Downregulation of transcripts was reversed by treatment with epigenetic
silencing inhibitors. The transcriptional expression of ﬁve genes (S100A4, S100A7,
S100A8, S100A9, and TNFSF7) was examined following treatment with the epigenetic
silencing inhibitors 5′-aza-dC and butyrate via semiquantitative RT-PCR. Cell lines used
are as follows: CTL, MCF-10A (untransformed) as control; AT1, MCF-10AT1 (benign
proliferation), 1k, MCF-10AT1kcl2 AT1 (benign proliferation); com, MCF-10DCIS.com
(carcinoma in situ); 1a, MCF-10CA1acl1 (invasive); 1d, MCF-10CA1d cl1 (invasive); and
1h, MCF-10CA1h cl2 (invasive carcinoma). GAPDHwas utilized as an internal control for
the PCR.
Fig. 7. The effect of exogenous expression of S100A8 and S100A9 on the colony
formation of MCF-10AT1 and MCF-10DCIS.com cells. MCF-10AT1 (benign tumor cells)
(A) and MCF-10DCIS.com (carcinoma in situ) (B) showing the loss of the expression of
S100A8 and S100A9 genes were transfected with a S100A8 and S100A9 expression
vector or the empty vector as indicated in Materials and methods. Relative number of
hygromycin-resistant colonies after transfection was calculated as the percentage of
colonies with respect to the empty vector-transfected cells and is shown in the inset.
424 D.K. Rhee et al. / Genomics 92 (2008) 419–428S100A8 and S100A9 inhibit cell growth in MCF-10AT1 and
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To gain further insight into the potential role of the selected genes
identiﬁed by ourmicroarray and expression analyses, we attempted to
reintroduce some of these genes into the MCF-10AT1 (benign
proliferation) and MCF-10DCIS.com (localized carcinoma) cell lines.
Expression vectors harboring S100A8 and S100A9 were indepen-
dently used for transfection of MCF-10AT1 and MCF-10DCIS.com cells
and empty vector was used as a negative control. Two days after
transfection, cells were selected with hygromycin B and resistant
colonies after 2 weeks were stained using crystal violet. Interestingly,
we found out that the number of the hygromycin-resistant colonies
transfected with S100A8 and S100A9 was signiﬁcantly reduced
relative to that with control vector in two independent experiments
(Fig. 7). The effect of S100A8 and S100A9 on colony formation was
somewhat different depending on the host cell lines used for
transfection. Namely, exogenous expression of S100A8 is more
effective in reduction of resistant colony number when compared
with S100A9 in the background of benign tumor cells (MCF-10AT1)
(42% vs 76%) while the effect is reversed when transfected with MCF-
10DCIS.com (57% vs 8%). Thus, these data support the hypothesis that
the loss of the expression of these genes in breast benign tumor and
cancer cells might be related to the cell proliferation.
Discussion
A comprehensive and consistent description of the gene expres-
sion signatures that underlie breast cancer development and
progression remains to be determined. A recent comparative micro-
array analysis of a large number of cancer cell lines and tumor tissues
provided insight into the transcript changes that occur during
development of cancer cells [8–10,13]. Comparison of a gene
expression proﬁling data from tumor tissue and normal tissue
permitted the discovery of a number of candidate biomarkers for
tumorigenesis and invasiveness. These kinds of comparative studies
have been plagued with complications due to the confounding effects
of different cell types or different genotypes. To overcome these
obstacles, we performed a comparative analysis of transcripts using a
series of isogenic breast epithelial cells that spanned the range from
untransformed outgrowths to benign proliferation, carcinoma in situ
and invasive carcinoma. Four distinct expression patterns were
revealed through clustering analysis. As mentioned previously,
classiﬁcation of these four groups is dependent on the upregulation
or downregulation associated with molecular events of transforma-tion and invasiveness during breast cancer development. Based on
these classiﬁcations, we conclude that Group I and Group III genes
exert positive roles on tumor progression (namely acting as
oncogenes) whereas Group II and IV genes play negative roles in
tumor progression (namely acting as tumor suppressors).
As mentioned above, the upregulation of Group I gene expression
is involved in the transition from untransformed outgrowths to
benign proliferating transformed cells. THBS1 is involved in angiogen-
esis, tumorigenesis, and inhibition of apoptosis (Fig. 4A) [23,24].
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the transcript and protein levels, supporting its potential role in breast
tumorigenesis (Figs. 4A and 5). The MIA protein negatively regulates
cellular anti-tumor immune reactions, and promotes the migration
and progression of melanomas [25]. Despite the detection of increased
mRNA levels, the MIA protein level remained constant during cancer
progression in our isogenic MCF10 model (Fig. 4A and data not
shown). This result indicates that MIA expression at the mRNA level
may be pseudo-effect and does not represent the actual protein levels.
MGP, a matrix Gla protein, is overexpressed in malignant human
breast cells [26]. CMTM7, a chemokine-like factor, is highly expressed
in leukocytes [27], and TACSTD1 codes for a carcinoma-associated
antigen that is important in breast cancer epithelial malignancies [28].
In addition, TMEM16A, a transmembrane protein, is highly expressed
in various cancer cells [29]. Similar to MIA, the TMEM16A protein level
was constant during progression of breast cancer cells, suggesting
pseudo-expression (Fig. 4A and data not shown). KLK5 belongs to
kallikrein family with serine proteinase activity, which has been
implicated in carcinogenesis and tumor progression, particularly in
invasion and angiogenesis [30]. CTSL2, a member of the peptidase C1
family, was induced in colorectal and breast carcinomas [31]. SPRY1, a
sprouty homolog acting as antagonist of FGF signaling, is moderately
expressed in prostate cancer tissues and cell lines [32]. CEACAM1, a
cell–cell adhesion molecule, was reported to be induced in some
epithelial cell malignancies, demonstrating a signiﬁcant association
with poor prognosis [33]. Thus, these ﬁndings demonstrate that these
selected genes of Group I may contribute to transformation and
progression of breast cancer cells.
In addition, the transcript level of the AXL receptor tyrosine kinase
increased just after the transition from MCF-10A into the benign
proliferation stage (Fig. 4A). These data are largely consistent with the
previous report that shows increased levels of AXL transcripts at the
transition from noninvasive MCF-7 cells to invasive MDA-MB-231
[10]. Consistent with these ﬁndings, AXL is an oncogene associated
with colon cancer, melanoma [34], and chronic myelogenous
leukemia [35]. Furthermore, follistatin (FST) transcripts highly
accumulated following the transition from benign to noninvasive
carcinoma cells (Fig. 4A). Recent reports indicated that FST is
expressed in liver tumors [36], and follistatin like 1 (FSTL1) was also
upregulated in invasive MDA-MB-231 cells compared with noninva-
sive MCF-7 cells [10]. Thus, these ﬁndings support a potential role of
the follistatin protein family in tumorigenesis.
While a set of oncogenes was already expressed in the benign cells,
another set of tumor-related genes (Group III) including NFE2L3,
TNFRSF12A, GPRC5A, CSF2, LIF, and MMP7 (Fig. 4B) was upregulated
following the transition to noninvasive stages. NFE2L3, a member of
the Maf proto-oncogene family, plays a signiﬁcant role in develop-
ment, differentiation, oncogenesis, and stress signaling [37].
TNFRSF12A, a member of tumor necrosis factor receptor superfamily,
plays an important role in immune and inﬂammatory processes,
oncogenesis, and cancer therapy resistance [38]. GPRC5A, amember of
the type 3 G protein coupling receptor family, is involved in embryonic
development and epithelial cell differentiation and was upregulated
in human tumor cell lines, including breast cancer cells [39]. The
cytokine CSF2 was reported to promote tumor progression and
mediate metastasis [40,41]. Another cytokine LIF regulates the
metastatic behavior of rhabdomyosarcoma cells and their metastasis
to the bone marrow [42]. In addition, MMP7, plasma matrix
metalloproteinase-7, was identiﬁed as a metastatic marker and
survival predictor in patients with renal cell carcinomas [43]. Our
data are consistent with the previous observations that show their
functions in tumorigenesis and progression of cancer cells, thus
implicating potential role of these genes in breast carcinogenesis.
VCAN and TNC were upregulated only in the benign cells (Fig. 4C).
VCAN, an abundant proteoglycan in the blood vessel wall, is highly
induced in patients with lymph node metastasis of endometrialcancer [44]. TNC is an extracellular matrix protein involved in tissue
interactions during fetal development and oncogenesis [45]. In
contrast, CSTA, a cysteine protease inhibitor and a member of the
human cystatin gene family, was suppressed only in the benign cells
(Fig. 4F). CSTA plays a role in development of the neonatal epidermis
[46]. Another member of this family, cystatin M, was downregulated
in breast cancer through frequent epigenetic inactivation [47,48].
These results implicate these proteins in the benign proliferation
stage of breast cancer although the mechanisms remain to be
elucidated.
In contrast, genes of the Group II and IV may function as tumor
suppressors during the transformation of normal MCF-10A cells and/
or progression to malignant breast cancer cells, respectively, because
these genes exhibited downregulated expression patterns during
progression of breast cancer cells. Among them, SCGB1A1, a potent
anti-inﬂammatory protein, is highly expressed in normal lung tissue
and downregulated in lung cancers (Fig. 4D; [49]). This ﬁnding
implicates SCGB1A1 in the development of cancer. TNFSF7 codes for
CD70 molecule which play a role in regulating B-cell activation and
cytotoxic function of natural killers [50]. TNFSF10 is a cytokine that
induces apoptosis in transformed and tumor cells [51]. GLI3 belongs to
a GLI-Kruppel family and codes for a C2H2-type zinc ﬁnger protein
that might act as DNA-binding transcriptional repressor and mediator
of sonic hedgehog (SHH) signaling [52]. In addition, FOLR1 codes for
folate receptor-alpha that its overexpression is associated with poor
outcome in breast cancer [53]. The data may support that down-
regulation of the selected genes from group II and IV is related to
growth in tumor cells, except for FOLR1.
Group II and IV contain S100A4, S100A7 (psoriasin), S100A8
(calgranulin A), and S100A9 (calgranulin B), which belong to a
calcium-binding protein family. Several reports implicated the S100
family proteins in tumor progression. S100A8 and S100A9 form stable
heterodomers and together contribute up to 40% of the total cytosolic
protein in neutrophils [54,55]. Furthermore, S100A8 and A9 are
upregulated in breast cancers, gastric cancers, lung adenocarcinomas,
colorectal cancers, prostate cancers, and skin cancer but down-
regulated in squamous oesophageal carcinoma [56–59]. Most of these
studies cannot exclude the possibility that the tissue samples used
contained some inﬂammatory cells that express S100A8 and S100A9
proteins at high levels; however, one study [56] that employed tissue
microarray analysis indicates that S100A8 and S100A9 are over-
expressed in 14–27% of breast tumor tissues. In contrast, another
recent report indicated that S100A7, S100A8, and S100A13 are
downregulated in invasive MDA-MB-231 cells compared with non-
invasive MCF-7 cells [10]. Additionally, S100A8 and S100A9 were
strong inducers of apoptosis in colon cancer cells [60]. Consistent with
these observations, our RT-PCR and protein analysis indicated the
downregulation of S100A8 and S100A9 during breast carcinogenesis
in the isogenic MCF10 model. Previous reports showed that S100A7
expression was upregulated only in ductal carcinoma in situ (DCIS) of
breast tumors and in gastric tumor tissues [57,58]. On the other hand,
Nagaraja et al. [10] demonstrated the downregulation of S100A7 in
invasive MDA-MB-231 compared with noninvasive MCF-7 cells.
Similarly, our data also supported these ﬁndings. S100A7 was
downregulated with the transition from untransformed MCF-10A to
benign proliferation (Fig. 6 and Supplemental Table 1S). Together, the
data suggest that the silencing of S100A7 is required for both initiation
of tumorigenesis and invasiveness in breast cancer cells. In addition,
S100A4, which was assigned to Group IV, was accordingly down-
regulated with the transition from benign to noninvasive carcinoma. A
previous report suggested that S100A4 may be involved in motility,
proliferation, and apoptosis, which is implicated in tumor metastasis,
a result inconsistent with our data [59]. In contrast a recent report has
revealed that S100A4 play a role in enhancing p53-dependent
apoptosis, implying its negative role in tumorigenesis [59]. Thus,
transcriptional downregulation of S100A4, S100A7, S100A8, and
426 D.K. Rhee et al. / Genomics 92 (2008) 419–428S100A9 appear to contribute to initiation and progression of breast
tumorigenesis.
As mentioned previously, epigenetic inactivation of tumor sup-
pressors is recognized as mechanism of tumor progression. In
particular, hypermethylation of CpG islands at tumor-suppressor
gene promoters plays an important role in the development of cancer
cells [21,22]. For example, the tumor suppressor S100A2 is often
silenced by CpG hypermethylation in several tumor types such as
breast, lung, and prostate cancers [61–64]. Since our RT-PCR and
protein analysis indicated that S100A4, S100A7, S100A8, and S100A9
were downregulated during breast carcinogenesis in the isogenic
MCF10 model (Figs. 4 and 5), we speculated that epigenetic silencing
via histone modiﬁcation and DNA hypermethylation may contribute
to the downregulation of these genes. Indeed, treatment of the cells
with the silencing inhibitors 5-aza-dC and sodium butyrate reversed
the transcriptional silencing of the TNFSF7, S100A4, S100A7, S100A8,
and S100A9 genes (Fig. 6). Together, these ﬁndings suggest that the
transcriptional silencing of S100A4, S100A7, S100A8, S100A9, and
TNFSF7 may contribute to initiation and malignancy of breast cancer.
The exact mechanism of this epigenetic inactivation and its effects on
breast carcinogenesis remain to be determined.
Recent reports indicate that methyl-CpG-binding domain proteins
(MBDs) are associated with aberrantly methylated tumor-suppressor
genes [65]. As a result, the MBD proteins were predicted to play a key
role in repressing tumor-suppressor genes that become hypermethy-
lated in cancer cells. A recent report showed identiﬁcation of novel
targets of epigenetic inactivation in human cancer using the combined
chromatin immunoprecipitation assay of MBDs with a CpG island
microarray [66]. They revealed that two MBD-associated, PAX6 and
PRLR, inhibit cell growth in a breast cancer cell line MBA-MB-231 [ref.
[66]]. Similar to these ﬁndings, we found that exogenous expression of
S100A8 and S100A9 inhibit cell proliferation in MCF-10AT1 (benign
tumor) and MCF-10DCIS.com (noninvasive carcinoma) cells (Fig. 7).
Our data may support the hypothesis that epigenetic inactivation of
these genes in breast tumor and carcinoma cells is related to cell
growth. The exact mechanism of the tumor-suppressor-like function
remains to be understood via further experiment.
In conclusion, we employed a series of isogenic human breast
cancer cell lines spanning the range from normal tissue to benign,
carcinoma in situ, and invasive carcinoma to generate a comprehen-
sive and novel description of the gene expression proﬁles associated
with transformation and progression to breast cancer. Four distinct
expression patterns were identiﬁed to reveal differences that occur
during progression of breast cancer cells. Among the many further
analyzed transcripts, downregulation of at least ﬁve genes, including
TNFSF7, S100A4, S100A7, S100A8, and S100A9, and upregulation of
KLK5 and THBS1 highlighted molecular events associated with
transformation and progression of breast cancer cells. More impor-
tantly, downregulation of these genes may occur through epigenetic
silencing such as DNA methylation and/or histone deacetylation. In
addition, colony formation assay showed that the loss of the
expression of S100A8 and S100A9 is related to cell growth. Thus,
our presented data support that epigenetic change in expression of
TNFSF7 and four S100 family genes may contribute to transformation
and progression of human breast cancer cells.
Materials and methods
Cell lines, culture, and drug treatment
A series of MCF10 cell lines including the initial untransformed
normal cell line, MCF-10A, the benign proliferation stages (MCF-10AT1
andMCF-10AT1kcl2), and the invasive carcinoma stages (MCF-10CA1h
cl2, MCF-10CA1d cl1, and MCF-10CA1a cl1) were kindly provided by
The Barbara Ann Karmanos Cancer Institute (Detroit, MI, USA). The
carcinoma in situ stage (MCF-10DCIS.com) cell line was purchasedfrom Asterand, Inc. (Detroit, MI, USA). MCF-10CA1a cl1, MCF-10CA1d
cl1, MCF-10CA1h cl2, and MCF-10DCIS.com cells were cultured in
minimal DMEM/F12 medium supplemented with 2 mM L-glutamine,
15 mMHEPES, 3.151 g/L-glucose, 5% horse serum, and 0.028M sodium
bicarbonate. In contrast, MCF-10A, MCF-10AT1, and MCF-10AT1kcl2
cells were grown in complete medium composed of the whole
minimal DMEM medium components supplemented with 100 ng/ml
cholera toxin, 20 ng/ml epidermal growth factor, 10 μg/ml insulin, and
0.5 μg/ml hydrocortisone. Cells were incubated with 5% CO2 at 37 °C.
For extraction of total RNA from drug-treated cells, the seven cell lines
were grown for four days in the presence of DNA methyltransferase
inhibitor 5′-aza-2′-deoxycytidine (5′-aza-dC; Sigma-Aldrich, USA) at a
ﬁnal concentration of 1 μM and then for one day in a medium
containing 5 mM sodium butyrate (Sigma-Aldrich, USA).
RNA isolation and ampliﬁcation
Total RNA was extracted using RNeasy mini kit (Qiagen, Valencia,
CA, USA) according to the manufacturer's instructions. After DNase
digestion and nuclei acid clean-up procedures, RNA samples were
quantiﬁed, aliquoted, and stored at −80 °C until use. For quality
control, RNA purity and integrity were evaluated using an Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA
was ampliﬁed to yield biotinylated cDNA and then puriﬁed using the
Illumina RNA ampliﬁcation kit (Ambion, Austin, TX, USA) according to
the manufacturer's instructions. Brieﬂy, 550 ng of total RNA was
reverse-transcribed to cDNA using a T7 oligo(dT) primer. Second-
strand cDNA was synthesized, in vitro transcribed, and labeled with
biotin-NTP. After puriﬁcation, the cDNA was quantiﬁed using an ND-
1000 Spectrophotometer (NanoDrop, Wilmington, DE, USA).
Microarray and data analysis
Microarray experiments and statistical analysis were carried out at
Macrogen Inc. (Seoul, Korea). We performed two independent
microarray experiments using HumanRef-8 V2 Beadchip array or
cancer-related gene chip array and presented the data from
HumanRef-8 V2 array. Total RNAwas isolated from three independent
cell culture for each cell line, mixed and then subjected to preparation
of cDNA probes andmicroarray experiment. The microarray datawere
conﬁrmed by RT-PCR for each selected gene: 38 of 51 genes tested
(about 75%) showed matched expression pattern between microarray
and RT-PCR.
Brieﬂy, 750 ng of labeled cDNA samples were hybridized to each
Sentrix® HumanRef-8 V2 BeadChip array for 16–18 h at 58 °C
according to the manufacturer's instructions (Illumina, Inc., San Diego,
CA, USA). The chip was designed based on the information in the
National Center for Biotechnology Information (NCBI) reference
sequence (RefSeq) database, Release 17 and contained gene-speciﬁc
50-mer oligo probes with 900,000 features covering more than
22,000 transcripts from the human genome. Detection of the array
signal was performed using Amersham ﬂuorolink streptavidin-Cy3
(GE Healthcare Bio-Sciences, Little Chalfont, UK) as recommended in
the BeadChip manual. Arrays were scanned with an Illumina Bead
Array Reader confocal scanner according to the manufacturer's
instructions (Illumina, Inc., San Diego, CA, USA). The quality of
hybridization and overall chip performance were monitored by visual
inspection of both internal quality controls and the raw scanned data.
Data were extracted using the BeadScan data acquisition software
ver.3.1 (Illumina, Inc., San Diego, CA, USA) and normalized using the
Quantile normalization [67]. Array data processing and analysis was
performed using the BeadStudio software (Illumina, Inc., San Diego,
CA, USA). Genes were ﬁltered out using the detection p-value
threshold (p valueN0.05) in at least four samples. Also, data were
ignored when genes displayed a negative signal value. Consequently,
11,940 probes were used in the ﬁnal analysis. Hierarchical clustering
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with the normalized signiﬁcant genes using the PermutMatrix R
package v. 2.4.0 (http://www.r-project.org/). Functional annotation of
proteins was assigned by using the Panther database (http://www.
pantherdb.org). The Avadis Prophetic ver.3.3 (Strand Genomics,
Bangalore, India) as statistical software was used.
Semiquantitative RT-PCR analysis
RNA was converted to cDNA via priming with Oligo dT primers
using the Superscript III ﬁrst-strand synthesis system (Invitrogen Inc.,
Carlsbad, CA, USA) according to the manufacturer's protocol. The
conditions for PCR ampliﬁcation and sequences of primer sets are
summarized in the Supplemental Table 4S.
Real-time quantitative PCR
Real-time quantitative PCR was performed using an Applied
Biosystems 7500 real-time PCR System (Applied Biosystems, Foster
city, CA, USA) with SYBR GREEN PCR master mix (Applied Biosystems,
Foster city, CA, USA) according to the manufacturer's protocol. Primer
sets were identical to those used for of standard PCR (Supplemental
Table 3S). Cycling parameters were 95 °C for 10 min, followed by 40
cycles of 95 °C for 15 s, 55 °C for 20 s, and 72 °C for 35 s. Finally, an
extension at 72 °C for 10 min completed the reaction. A water control
and melting curve analysis were always performed to conﬁrm the
speciﬁcity of the PCR. The glyceraldehydes 3-phosphate dehydrogen-
ase (GAPDH) primer set was used as an internal control to normalize
the difference in the amount of cDNA contained in each initial reaction.
Immunoblot analysis
Cells were harvested and resuspended in lysis buffer containing
150 mM NaCl, 10 mM Tris (pH7.5), 0.2% Triton X-100, 0.3% NP-40,
0.2 mM Na3VO4, and 1 mM PMSF. Lysates were incubated on ice for
30 min and centrifuged at 13,000 rpm for 20 min at 4 °C. Protein
concentrations were measured with the Bio-Rad protein assay dye
reagent (Bio-Rad Laboratories Inc., Hercules, CA, USA). Fifty μg of
protein were separated on a 12% NuPAGE Bis-Tris Gel (Invitrogen Inc.,
Carlsbad, CA, USA) and blotted onto an Immobilon-P transfer
membrane (Millipore, Bedford, MA, USA). The blots were blocked
with 5% skim milk at room temperature for 1 h and then hybridized
with primary antibodies (THBS1, 1:500; KLK5, 1:500; S100A4, 1:100;
S100A8, 1:100; S100A9, 1:200; MIA, 1:200; MECP2, 1:1000;
TMEM16A, 1:500; GAPDH, 1:10,000; Tubulin, 1:10,000) overnight at
4 °C. After washing with phosphate-buffered saline (PBS: 137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4, pH 7.4)
supplemented with 0.1% Tween20 (PBST), the blots were incubated
with the corresponding secondary antibodies (1:10,000) and then
washed again with PBST buffer. The peroxidase-catalyzed chemilu-
minescence signal was detected using an Amersham ECL™ western
blotting detection reagent (GE Healthcare Bio-Sciences, Little Chal-
font, UK) according to the manufacturer's instructions.
Colony formation assay
The transfection of the pCMV-Flag control vector, pCMV-Flag-
S100A8 and pCMV-Flag-S100A9, also harboring hygromycin-resistant
gene into the MCF-10AT1 (benign tumor cell line) or MCF-10DCIS.com
(carcinoma in situ) was carried out using magnetofection reagent
(Chemicell). Brieﬂy, cells were seeded in a six-well plate a day prior to
transfection at a density of 5×105 cells per well. Four μg of puriﬁed
plasmid DNAwas used with 4 μl of PolyMAG reagent, according to the
manufacturer's instructions. Two days after transfection, cells were re-
inoculated in 100-mm dishes at a density of 4×104 cells per dish, and
then cultured in selective media containing 50 μg/ml hygromycin B foradditional 14 days. At the end of incubation, colony formation was
assessed by a colorimetric assay using crystal violet.
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